Latest Content

Dupilumab cut hand eczema severity (59.8% vs 15.2% with placebo), regardless of a patient's atopic history.

Patient understanding should be treated as a measurable equity outcome, not an assumed byproduct of care.

Christos Vaklavas, MD, discussed barriers limiting rural oncology access and challenges to adopting resource-intensive therapies.

The Right Care Initiative provides a proven, scalable framework for reducing preventable cardiovascular deaths. By integrating interorganizational learning, pharmacist-led care, and precision screening (coronary artery calcium imaging), the model bridges the 17-year implementation gap between clinical evidence and improved population health.

This report suggests that a unified approach to comprehensive data collection, led by a state Medicaid agency, can improve opportunities for engagement in pregnancy care management.

FDA cut required monitoring for tarlatamab’s first 2 doses from 22-24 hours to 6-8 hours, easing a barrier to community cancer care.

Endometriosis was found to nearly double absenteeism and work-ability impairment, according to one study.

Shiven B. Patel, MD, MBA, shares strategies for closing biomarker testing gaps, including among patients with non–small cell lung cancer.

The ESC's 2026 heart failure guidelines overhaul HF classification, rename therapy categories, and add a new HFpEF recommendation.